VP

Vesale Pharmaceutica

BE0452.282.591

Gross margin
€ 2.20M ↑ 109% 2025 Total € 20.91M
Profit
€ -363K ↓ 250% 2025 Total € -4.33M
EBITDA
€ 1.42M ↑ 172% 2025 Total € 9.02M
EBIT
€ 225K ↓ 13% 2025 Total € -2.65M
Net profit
€ -363K ↓ 250% 2025 Total € -4.33M
Capex
€ 377K ↑ 106% 2025 Total € 10.78M
Assets
€ 4.02M ↓ 11% 2025
Equity
€ 3.10M ↓ 10% 2025
Debt
€ 921K ↓ 13% 2025
Cash
€ 1.51M ↑ 1147% 2025
Cashflow
€ 827K ↑ 64% 2025 Total € 7.74M
Working capital
€ 2.32M ↓ 7% 2025
Current ratio
3.52 ↑ 2% 2025
Quick ratio
2.50 ↓ 24% 2025
Working capital ratio
3.52 ↓ 12% 2025
Debt
€ 921K ↓ 13% 2025
Short-term debt
€ 920K ↑ 5% 2025
Long-term debt
€ 44K ↓ 50% 2024
Debt / EBITDA
0.65 ↓ 68% 2025
Solvability
77.1% ↑ 0.5 pt 2025
Long term debt ratio
0.01 ↓ 67% 2024
Gross profitability
26.7% ↑ 12.2 pt 2025
Net profitability
-11.7% ↓ 18.7 pt 2025
Return On Assets (ROA)
-9.02 ↓ 268% 2025
Return On Equity (ROE)
-11.69 ↓ 267% 2025
Customer credit
87.06 ↑ 49% 2021
Days Sales Outstanding (DSO)
87.06 ↑ 49% 2021
Days Sales of Inventory (DSI)
48.63 2021
Taxes
€ 0 2024 Total € 57K
Salaries and Social Security Contributions
€ 33K ↓ 12% 2025 Total € 1,000K
Employees
2.50 2025
Staff cost per employee
€ 13K ↓ 12% 2025